# HIV treatment and prevention advancements

> Live situation record from CLSTR: https://clstr.news/situations/hiv-treatment-and-prevention-advancements
> Updated: 2026-10-16T00:06:04.000Z. Sources: 7. Developments: 2.

Developments in HIV treatment and prevention have focused on the efficacy and accessibility of long-acting injectables compared to traditional daily oral medications.

A clinical trial involving adolescents in Kenya, South Africa, Uganda, and Zimbabwe found that eight-weekly injections of cabotegravir and rilpivirine were more effective at suppressing the virus than daily tablets. The study reported only a 1% viral rebound rate for the injectable group versus 6% for those on daily pills, with 94% of participants preferring the less frequent dosing.

Further research is exploring even longer dosing intervals. The CUATRO study is testing formulations that could extend administration to once every four months. Additionally, the WHO has recommended the semi-annual injection lenacapavir for prevention, though concerns persist regarding global equity and high costs, which can exceed $28,000 annually in the United States.

## Timeline

### 2026-10-16: HIV research advances with vaccine breakthroughs and long-acting injectables

Researchers report progress in HIV vaccine development via germline targeting, while clinical trials in Brazil test ultra-long-acting injectables to reduce dosing frequency to every four months.

2 sources. https://clstr.news/cluster/hiv-research-advances-with-vaccine-breakthroughs-and-long-acting-injectables

### 2026-09-20: HIV injections outperform daily pills in African adolescent trial

An African clinical trial found that eight-weekly HIV injections outperformed daily tablets in suppressing the virus among adolescents, with 94% of participants preferring the injectable method.

5 sources. https://clstr.news/cluster/hiv-injections-outperform-daily-pills-in-african-adolescent-trial

---
Cite as: HIV treatment and prevention advancements. CLSTR, https://clstr.news/situations/hiv-treatment-and-prevention-advancements